Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. (Q38123513)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Jonathan L Curry

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Carlos A Torres-Cabala

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Kevin B Kim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michael T Tetzlaff

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Madeleine Duvic

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

David S Hong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Victor G Prieto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

24 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Dermatology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

376-384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23879247%20AND%20SRC:MED&resulttype=core&format=json

Skin reactions to the new biologic anticancer drugs

5 March 2020

cites work

1 reference

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.

21 January 2018

1 reference

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

21 January 2018

1 reference

Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients

21 January 2018

1 reference

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

21 January 2018

1 reference

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

21 January 2018

1 reference

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

21 January 2018

1 reference

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

21 January 2018

1 reference

Sorafenib-induced premalignant and malignant skin lesions

21 January 2018

1 reference

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

21 January 2018

1 reference

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

The histologic spectrum of epithelial neoplasms induced by sorafenib

21 January 2018

1 reference

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors

21 January 2018

1 reference

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via the K-Ras pathway

21 January 2018

1 reference

Skin toxicities associated with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma

21 January 2018

1 reference

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

Meta-analysis of dermatological toxicities associated with sorafenib

21 January 2018

1 reference

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

21 January 2018

1 reference

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

21 January 2018

1 reference

Paradoxical activation of Raf by a novel Raf inhibitor

21 January 2018

1 reference

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

21 January 2018

1 reference

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds

21 January 2018

1 reference